Combined Use of Potassium Nitrate Gel and Diode Laser for Dentin Hypersensitivity
Launched by UNIVERSITY OF PAVIA · May 4, 2025
Trial Information
Current as of July 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the combined use of a special gel and a laser treatment to help reduce dentin hypersensitivity, which is a common issue that causes discomfort when teeth are exposed to air or certain foods. The researchers want to see if using a potassium nitrate gel along with a diode laser makes a difference in relieving this sensitivity compared to using the gel alone. Participants in the trial will receive either the gel with the active laser treatment or the gel with a sham (inactive) laser treatment.
To be eligible, participants need to be adults with good oral hygiene who have at least one tooth that is sensitive. They should not be taking pain medications, undergoing orthodontic treatment, or have certain dental conditions, like treated teeth or restorative materials. Throughout the trial, participants will have their sensitivity measured several times after the treatment to see how well it worked and how it affects their daily lives. This study aims to improve the understanding of how these treatments can help those suffering from dentin hypersensitivity.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with good oral hygiene
- • Presence of at least one tooth affected by dentin hypersensitivity
- • Signed informed consent
- Exclusion Criteria:
- • Use of analgesic medication
- • Ongoing orthodontic treatment
- • Non-vital (endodontically treated) teeth
- • Teeth with restorative materials on the surface
- • Pregnant or breastfeeding women
About University Of Pavia
The University of Pavia, a prestigious institution renowned for its commitment to academic excellence and research innovation, serves as a prominent clinical trial sponsor. With a strong emphasis on advancing medical knowledge and improving patient care, the university leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical research. Collaborating with leading healthcare professionals and institutions, the University of Pavia is dedicated to exploring novel therapeutic approaches and fostering the translation of scientific discoveries into clinical practice, ultimately aiming to enhance health outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pavia, Lombardy, Italy
Patients applied
Trial Officials
Andrea Scribante, Associate Professor
Principal Investigator
University of Pavia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported